Grafa News and Videos — Page 255

Bio-Techne (NASDAQ:TECH) shareholders approved the proposed acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026.

Immunovant (NASDAQ:IMVT) reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, with the study failing to meet its primary endpoint.

Oruka Therapeutics (NASDAQ:ORKA) reported positive Week 28 results from the Phase 2a EVERLAST-A trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

AC Immune (NASDAQ:ACIU) reported that all primary endpoints were met at week 100 in Part 1 of its Phase 2 VacSYn trial evaluating ACI-7104 in early Parkinson’s disease.

Sharon AI (NASDAQ:SHAZ) is collaborating with VAST Data to offer VAST DataEnclave confidential AI capabilities through its AI Factory platform across Australia and Asia-Pacific.

Cintas (NASDAQ:CTAS) reported fiscal 2027 first-quarter revenue of $3.01 billion, an increase of 10.9% from $2.72 billion in the prior-year period.

Viasat (NASDAQ:VSAT) secured a $42 million initial task order under a seven-year U.S. Marine Corps satellite communications contract announced on September 23, 2026.

SLB (NYSE:SLB) received a contract from OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman.

HUHUTECH (NASDAQ:HUHU) reported first-half 2026 revenue of $10.67 million, an increase of 8.6% from the prior-year period, supported by contributions from new international operations.

Roivant (NASDAQ:ROIV) reported topline results from Immunovant’s proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, with the study failing to meet its primary endpoint.